Clinical Trials
52 trialsA Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
A Phase I Study of BR108 in Hematological Malignancies
BioRay Pharmaceutical Co., Ltd.
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
Incyte Corporation
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Incyte Corporation
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
Shanghai EpimAb Biotherapeutics Co., Ltd.
SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
Hangzhou Sumgen Biotech Co., Ltd.
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
Gilead Sciences
CYNK001AML01
Celularity Incorporated
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
Takeda
Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation
Prolacta Bioscience
ERASER
Antengene Corporation
ATRIUM
Antengene Corporation
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials
GlaxoSmithKline
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Prelude Therapeutics
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Bellicum Pharmaceuticals
Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2
MediMergent, LLC
A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
AstraZeneca
Thrombosomes® in Bleeding Thrombocytopenic Patients Study
Cellphire Therapeutics, Inc.
A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
AbbVie
Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
Fate Therapeutics
MT-3724NHL001
Molecular Templates, Inc.
HATCY
Kiadis Pharma
A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)
Genenta Science
The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
Fate Therapeutics
MIPLATE
Terumo BCTbio
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
Kiadis Pharma
FLORET
Menarini Group
SIGNATURE
Novartis
SIGNATURE
Pfizer
A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
SecuraBio
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
Exact Sciences Corporation
Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors
Adaptimmune
Study of IV CBL0137 in Previously Treated Hematological Subjects
Incuron
Japanese AML
Gilead Sciences
Ceritinib Rare Indications Study in ALK+ Tumors
Novartis
To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.
Acrotech Biopharma Inc.
ABC123
Cellectis S.A.
CBGJ398XUS04
Novartis
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Incyte Corporation
A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy
Xian-Janssen Pharmaceutical Ltd.
A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies
Fate Therapeutics
Trial of Pimasertib in Hematological Malignancies
EMD Serono
SIGNATURE
Novartis
A Study of BMS-863233 in Patients With Hematologic Cancer
Bristol-Myers Squibb
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
Celgene
Dose Escalation of IPI-493 in Hematologic Malignancies
Infinity Pharmaceuticals, Inc.
Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
Sanofi
A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)
Gilead Sciences